Tocilizumab: Efficacy and Tolerance in Rheumatoid Arthritis in Current Practice


Rheumatoid arthritis


How to Cite

Akasbi N, Mounir A, Omboumahou Bakale FE, El Fakir S, Harzy T. Tocilizumab: Efficacy and Tolerance in Rheumatoid Arthritis in Current Practice. Integr J Med Sci [Internet]. 2019 Apr. 26 [cited 2022 Oct. 5];6. Available from:


Introduction: The aim of this study was to evaluate in “real life” the efficacy and the tolerance of Tocilizumab (TCZ) in the treatment of rheumatoid arthritis (RA).
Materials and methods: A cross-sectional study including patients with RA patients treated with TCZ at the commended dose of 8 mg/kg/ 4 weeks. The therapeutic response was evaluated by the EULAR DAS 28 ‐CRP/ VS at month 3 and month 6 of treatment.
Results: RA was in most cases severe (76,5 %), seropositive (88,2 %) and erosive (81,3 %). TCZ was prescribed as an alternative to a previous biotherapy in 23 % of the patients and in monotherapy in 76, 5 % of the patients. After treatment follow-up at 3 and 6 months, the different parameters observed were significantly improved including: VAS (visual analogue scale) pain (p=0,000), CRP (mg/L) p=0,000), ESR (mmH1) (p=0,000), DAS 28 CRP (p=0,000), and DAS 28 ESR (p=0,000). Apart from a worsening of renal function in a patient contraindicated continuation of tocilizumab, no serious side effects were noted.
Conclusion: Our study confirmed the efficacy and tolerance of TCZ therapy in Moroccan patients suffering from RA.
Keywords: rheumatoid arthritis, tocilizumab, efficacy, tolerance


Ghita Harifi, Emmanuel Chatelus, Christelle Sordet, Jacques-Eric Gottenberg, Jean Sibilia. De nouvelles cibles cytokiniques dans la polyarthrite rhumatoïde : le tocilizumab et les autres inhibiteurs des cytokines. Rev Rhumat. 2010 May; 77(1): s32-s40.

Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003 Jul;30 (7):1426-35. [Accessed 01 Jul 2021]. Available from :

Clément Chopin, Loïc Pauvele, Sarah Jaulerry, Pascal Brochot, Jean-Paul Eschard, Jean-Hugues Salmon et al. [Effectiveness, therapeutic maintenance and reasons for stopping tocilizumab (TCZ): A retrospective and monocentric study in 88 patients followed for rheumatoid arthritis (RA) at the Reims university hospital]. Thérapie. May-June 2018; 73 (3): 231-236.

Kihara M, Davies R, Kearsley-Fleet L, Watson KD, Lunt M, Symmons DP, et al. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin Rheumatol. 2017 Feb;36(2):241-250.

Lannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. Clin Rheumatol. 2018 Feb;37(2):315-321.

Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM. Treatment of Rheumatoid Arthritis WithAnti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. Arthritis Care Res (Hoboken). 2017 Oct; 69(10):1484-1494.

Nakashima Y, kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima Y, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Modern Rheumatol. 2010 Aug; 20(4):343-52.

Bykerk VP, Ostör AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis. 2012; 71(12):1950-1954.

Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin-6 receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIb real-life study (TAMARA). Ann Rheum Dis. 2011 May; 70(5): 755-9.

Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis, 2010 Jan; 69(1): 88-96.

Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011 Apr;21 (2):122-33.

Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Kraishi M, Gómez-Reino J, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013 Jun; 40(6):768-80.

Uda H, Saiki O. Tocilizumab Infusion Intervals Can be Extended to 5 or 6 Weeks in RA Patients Who Sustained Low Disease Activity By 4 Weeks Interval of Tocilizumab Infusion. Arthritis Rheumatol. 2016 Sep; 68. [Available 1 Jul 2021]. Available From:

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2019 Nessrine Akasbi et al.


Download data is not yet available.